VativoRx, LLC

04/11/2026

FDA expanded BESREMi® (ropeginterferon alfa-2b) to essential thrombocythemia, a rare blood disorder causing excess platelets. First new ET treatment in nearly 30 years. In trials, 37.4% had a durable response vs. 3.6% on anagrelide.

https://vativorx.com/pharmacy-bulletin-11-04-2026/

On Aug. 31, 2026, the US Food and Drug Administration (FDA) approved PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults who have essential thrombocythemia (ET), expanding its label beyond the existing indication for polycythemia vera.

02/11/2026

FDA approved Zanvastro™ (zilganersen) — the first treatment for Alexander disease, an ultra-rare neurologic disorder. This antisense therapy targets the abnormal protein driving progression. Given every 3 months. Launch expected in weeks.

https://vativorx.com/pharmacy-bulletin-11-02-2026/

On Sept. 3, 2026, the US Food and Drug Administration (FDA) approved Ionis Pharmaceuticals' Zanvastro™ (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro is an RNA-targeted antisense oligonucleotide designed to reduce production of the abnorma...

23/10/2026

CMS finalized a mandatory Part B rebate model tied to international prices. The rebates are owed to CMS, which makes it a different conversation from plan-level rebate receipt.

New Rebate Report: https://www.linkedin.com/pulse/cms-finalized-new-part-b-rebate-model-rebates-owed-vativorx-llc-iiuee

22/10/2026

FDA approved Mimrylo™ (rusfertide) for polycythemia vera, the first hepcidin mimetic, a weekly shot that limits excess red blood cell production. In trials, 76.9% of patients avoided phlebotomy vs. 32.9% on placebo.

https://vativorx.com/pharmacy-bulletin-10-22-2026/

On Aug. 28, 2026, the US Food and Drug Administration (FDA) approved Takeda Pharmaceuticals’ Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults who have polycythemia vera (PV). Mimrylo is a first-in-class hepcidin mimetic that regulates iron availability to limit excessive red b...

07/10/2026

FDA-approved Bixlenvo™ — the first single-tablet HIV regimen for virologically suppressed adults who can't use existing STRs. Pairs bictegravir + lenacapavir with no cross-resistance to other antiretrovirals. Launch imminent at $4,595/month.

https://vativorx.com/pharmacy-bulletin-10-07-2026/

The US Food and Drug Administration (FDA) approved Gilead Sciences’ Bixlenvo™ (bictegravir 75mg/lenacapavir 50mg) tablets, on Aug. 27, 2026, for the treatment of HIV in virologically suppressed adults, including those maintained on complex antiretroviral regimens who cannot use currently availab...

01/10/2026

FDA approved Lisraya™ (brepocitinib) — the first targeted therapy for dermatomyositis, a rare autoimmune disease causing muscle weakness and painful skin lesions. In trials, 55% of patients achieved meaningful improvement vs. 30% on placebo.

https://vativorx.com/pharmacy-bulletin-10-01-2026/

On Aug. 27, 2026, the FDA approved Roivant/Priovant's Lisraya™ (brepocitinib) for the treatment of adults with dermatomyositis. Dermatomyositis is a rare systemic autoimmune disease characterized by chronic inflammation that can cause progressive muscle weakness and painful, pruritic skin lesions,...

29/09/2026

FDA approved Rasonque™ (daraxonrasib) for metastatic pancreatic cancer, the first oral RAS inhibitor to target both wild-type and mutant RAS proteins. In trials, it nearly doubled median overall survival vs. standard chemo (13.2 vs. 6.7 months).

https://vativorx.com/pharmacy-bulletin-09-29-2026/

On Aug. 26, 2026, the US Food and Drug Administration (FDA) approved Revolution Medicines' Rasonque™ (daraxonrasib) for the treatment of adults who have metastatic pancreatic adenocarcinoma (PDAC) and have received at least one prior systemic therapy or are not candidates for multiagent systemic t...

25/09/2026

Lerochol® (lerodalcibep) just got an autoinjector, once-monthly, self-administered, and room-temperature stable for up to 90 days. First PCSK9 inhibitor in this format. Available January 2027 at $199/month cash price.

https://vativorx.com/pharmacy-bulletin-09-25-2026/

On Aug. 17, 2026, the US Food and Drug Administration (FDA) approved a new formulation of LIB Therapeutics' Lerochol® (lerodalcibep-liga) as a 300mg/1.2mL autoinjector for use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults who have hypercholestero...

24/09/2026

FDA approved Genglycos™, a one-time gene therapy for GSDIa, an ultra-rare disorder in which the body can't regulate blood sugar without constant cornstarch intake. In trials, it cut cornstarch needs by up to 61%. List price: $2.7M.

https://vativorx.com/pharmacy-bulletin-09-24-2026/

On Aug. 19, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to Genglycos™ (pariglasgene brecaparvovec-opnr – Ultragenyx Pharmaceuticals), an adeno-associated vector (AAV)8 liver-directed gene therapy, to reduce daily cornstarch intake as an adjunct to nutritional man...

22/09/2026

Most plans have the pharmacy side handled. The infused and injected drugs billed under the medical benefit are a different story.

That's the conversation we want to have at SIIA 2026 - Phoenix, October 11–13.

John Srouji and Jason Baez will be onsite all three days. If specialty drug spend is on your list this year, let's find time.

Full post in the comments 👇